Breda

argenx raises $750 million in gross proceeds in a global offering

Retrieved on: 
Thursday, May 28, 2020
Finance, Banks, Money, Investment banks, Wedbush Securities, ADSS, Kempen & Co, Autoimmunity, Security, BofA Securities, Immunology, Nomura

Each of the ADSs offered in the offering represents the right to receive one ordinary share, nominal value of 0.10 per share.

Key Points: 
  • Each of the ADSs offered in the offering represents the right to receive one ordinary share, nominal value of 0.10 per share.
  • J.P. Morgan, Cowen and BofA Securities are acting as joint bookrunning managers for the offering.
  • Stifel, JMP Securities, Wedbush PacGrow, Nomura and Kempen & Co are acting as co-managers for the offering.
  • argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer.

argenx announces launch of proposed global offering

Retrieved on: 
Tuesday, May 26, 2020
Security, Stock market, ADSS

The global offering will be comprised of an offering of ordinary shares represented by ADSs in the United States and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area.

Key Points: 
  • The global offering will be comprised of an offering of ordinary shares represented by ADSs in the United States and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area.
  • J.P. Morgan, Cowen and BofA Securities are acting as joint bookrunning managers for the offering.
  • argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer.
  • No action has been or will be taken to offer the ordinary shares to a retail investor established in the European Economic Area as part of the global offering.

argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis

Retrieved on: 
Tuesday, May 26, 2020
Autoimmune diseases, Myasthenia gravis, RTT, GMG, Acetylcholine receptor, Myasthenia, ACHR, Biology, Ocular myasthenia

ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score among acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients.

Key Points: 
  • ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score among acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients.
  • With the ADAPT trial, we set out to evaluate efgartigimods ability to redefine the treatment paradigm for people living with gMG.
  • All of us at argenx want to thank the patients and healthcare providers who participated in the ADAPT trial.
  • The Phase 3 ADAPT trial was a randomized, double-blind, placebo-controlled, multi-center, global trial evaluating the safety and efficacy of efgartigimod in patients with gMG.

argenx reports first quarter 2020 financial results and provides business update

Retrieved on: 
Thursday, May 14, 2020
Immunology

Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update.

Key Points: 
  • Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update.
  • This is an important milestone as it will precipitate our transition from a late-stage development company towards an integrated commercial organization.
  • argenx commitment to its people, patients and business
    Despite the challenges of the COVID-19 pandemic, argenx remains focused on executing on its argenx 2021 vision to become a fully integrated, global immunology company.
  • argenx conducts clinical trials globally, including in areas impacted by COVID-19 in North America, Europe and Japan.

argenx reports full year 2019 financial results and provides fourth quarter business update

Retrieved on: 
Thursday, February 27, 2020
Financial regulation, International Financial Reporting Standards, Accounting, International Accounting Standards Board, Business, Economy, International Public Sector Accounting Standards

Research and development expenses totaled 197.7 million and 83.6 million for the years ended December 31, 2019 and 2018, respectively.

Key Points: 
  • Research and development expenses totaled 197.7 million and 83.6 million for the years ended December 31, 2019 and 2018, respectively.
  • Selling, general and administrative expenses totaled 64.6 million and 27.5 million for the years ended December 31, 2019 and 2018, respectively.
  • In addition to reporting financial figures in accordance with IFRS as issued by the IASB, argenx also reports financial figures in accordance with IFRS as adopted by the EU for statutory purposes.
  • argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

argenx announces closing of global offering

Retrieved on: 
Tuesday, November 12, 2019
European Economic Area, Multi-speed Europe, Organizations, Equity securities, Europe

The global offering consisted of (i) a public offering of 2,010,057 ADSs in the United States and certain other countries outside the European Economic Area (EEA) at a price to the public of $121.00 and (ii) a concurrent private placement of 2,589,943 of ordinary shares in the EEA at an offering price of 109.18.

Key Points: 
  • The global offering consisted of (i) a public offering of 2,010,057 ADSs in the United States and certain other countries outside the European Economic Area (EEA) at a price to the public of $121.00 and (ii) a concurrent private placement of 2,589,943 of ordinary shares in the EEA at an offering price of 109.18.
  • The gross proceeds from the global offering were approximately $557 million (approximately 502 million).
  • Kempen acted as lead manager for the offering and Wolfe Capital Markets and Advisory acted as co-manager.
  • No action has been taken to offer the shares to a retail investor established in the European Economic Area as part of the global offering.

argenx announces full exercise of underwriters’ option to purchase additional ADSs

Retrieved on: 
Friday, November 8, 2019
ADSS, Security, Shelf registration, U.S. Securities and Exchange Commission

This option exercise brings the anticipated total gross proceeds from the global offering to approximately $557 million (approximately 502 million) from the sale of an aggregate of 4,600,000 ordinary shares (including in the form of ADSs).

Key Points: 
  • This option exercise brings the anticipated total gross proceeds from the global offering to approximately $557 million (approximately 502 million) from the sale of an aggregate of 4,600,000 ordinary shares (including in the form of ADSs).
  • The closing of the global offering, including with respect to the ADSs subject to the option, is expected to occur on November 12, 2019, subject to customary closing conditions.
  • The securities were offered pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC).
  • argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer.

argenx raises $484 million in gross proceeds in a global offering

Retrieved on: 
Thursday, November 7, 2019
Finance, Money, Primary dealers, Investment banks, Evercore, ADSS, Private placement, Security, Morgan Stanley, BofA Securities

Each of the ADSs offered in the offering represents the right to receive one ordinary share, nominal value of 0.10 per share.

Key Points: 
  • Each of the ADSs offered in the offering represents the right to receive one ordinary share, nominal value of 0.10 per share.
  • The U.S. offering and the European private placement are currently expected to close simultaneously on November 12, 2019, subject to customary closing conditions.
  • Morgan Stanley, Cowen, BofA Securities and Evercore are acting as joint bookrunning managers for the offering.
  • Kempen is acting as lead manager for the offering and Wolfe Capital Markets and Advisory is acting as co-manager.

argenx reports third quarter 2019 financial results and provides business update

Retrieved on: 
Thursday, October 24, 2019
Asset, Cash, Cash and cash equivalents

Selling, general and administrative (SG&A) expenses totaled 41.7 million and 18.2 million for the nine months ended September 30, 2019 and 2018, respectively.

Key Points: 
  • Selling, general and administrative (SG&A) expenses totaled 41.7 million and 18.2 million for the nine months ended September 30, 2019 and 2018, respectively.
  • For the nine months ended September 30, 2019, financial income amounted to 10.9 million, compared to 2.0 million for the nine months ended September 30, 2018.
  • The increase of 8.9 million related primarily to an increase in interest received on cash, cash equivalents and current financial assets.
  • argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, September 3, 2019
Tolerx, Immunomedics

Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer,will present at the Morgan Stanley 17th Annual Global Healthcare Conference on Monday, September 9, 2019 at 10:30 am ET in New York.

Key Points: 
  • Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer,will present at the Morgan Stanley 17th Annual Global Healthcare Conference on Monday, September 9, 2019 at 10:30 am ET in New York.
  • The live webcast may be accessed on the homepage of the argenx website at www.argenx.com .
  • Shortly after the presentation, a replay of the webcast will be available for 90 days on the argenx website .
  • argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer.